Phase 3 Readout

AVBP: Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety

Name: Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety
Start: 2028-02-15
End: 2028-02-15

February 15, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 15, 2028
Company: ArriVent BioPharma, Inc. (AVBP)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety

February 15, 2028

AVBP overview →

Company: ArriVent BioPharma, Inc. (AVBP)
Indication: Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations